Clinical Trial Update: Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluates genetically modified T-cells (CAR-T) in patients with recurrent or refractory malignant glioma. Results have been posted (2024-10-30) an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma
• Who Grade Ii Glioma
• Who Grade Iii Glioma

Drugs mentioned

• Genetically Modified T-Cells (CAR-T therapy) (CAR-T cell therapy)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Glioblastoma, Recurrent Malignant Glioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-30